Nykode Therapeutics AS

Nykode Therapeutics ASverified

NYKD.OL

Price:

$2.438

Market Cap:

$78.91M

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar ...[Read more]

Industry

Biotechnology

IPO Date

2020-10-07

Stock Exchange

OSL

Ticker

NYKD.OL

The PE Ratio as of December 2025 (TTM) for Nykode Therapeutics AS (NYKD.OL) is -8.13

According to Nykode Therapeutics AS’s latest financial reports and current stock price. The company's current PE Ratio is -8.13. This represents a change of 2.47% compared to the average of -0.32 of the last 4 quarters.

Nykode Therapeutics AS (NYKD.OL) Historical PE Ratio (quarterly & annually)

How has NYKD.OL PE Ratio performed in the past?

The mean historical PE Ratio of Nykode Therapeutics AS over the last ten years is -47.35. The current -8.13 PE Ratio has changed 1.62% with respect to the historical average. Over the past ten years (40 quarters), NYKD.OL's PE Ratio was at its highest in in the June 2025 quarter at 17.40. The PE Ratio was at its lowest in in the June 2015 quarter at -101.84.

Quarterly (TTM)
Annual

Average

-47.35

Median

-18.57

Minimum

-256.63

Maximum

17.00

Nykode Therapeutics AS (NYKD.OL) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Nykode Therapeutics AS PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 0%

Maximum Annual PE Ratio = 17.00

Minimum Annual Increase = -1609.57%

Minimum Annual PE Ratio = -256.63

Quarterly (TTM)
Annual
YearPE RatioChange
2024-2.23-87.26%
2023-17.52-10.64%
2022-19.61-92.36%
2021-256.63-1609.57%
202017.00-207.78%
2019-15.77-41.14%
2018-26.80-53.21%

Nykode Therapeutics AS (NYKD.OL) Average PE Ratio

How has NYKD.OL PE Ratio performed in the past?

The current PE Ratio of Nykode Therapeutics AS (NYKD.OL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-13.12

5-year avg

-55.80

10-year avg

-47.35

Nykode Therapeutics AS (NYKD.OL) PE Ratio vs. Peers

How is NYKD.OL’s PE Ratio compared to its peers?

Nykode Therapeutics AS’s PE Ratio is less than Hofseth BioCare ASA (-4.79), greater than Lytix Biopharma AS (-9.59), less than Gentian Diagnostics ASA (20.03), less than BerGenBio ASA (-0.43), greater than Navamedic ASA (-14.68), less than Arctic Bioscience AS (-2.38), less than PCI Biotech Holding ASA (-0.46), greater than Thor Medical ASA (-34298.34), less than ArcticZymes Technologies ASA (571.28), less than ContextVision AB (publ) (29.64),

Build a custom stock screener for Nykode Therapeutics AS (NYKD.OL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nykode Therapeutics AS using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nykode Therapeutics AS (NYKD.OL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nykode Therapeutics AS or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Nykode Therapeutics AS's PE Ratio?

How is the PE Ratio calculated for Nykode Therapeutics AS (NYKD.OL)?

What is the highest PE Ratio for Nykode Therapeutics AS (NYKD.OL)?

What is the 3-year average PE Ratio for Nykode Therapeutics AS (NYKD.OL)?

What is the 5-year average PE Ratio for Nykode Therapeutics AS (NYKD.OL)?

How does the current PE Ratio for Nykode Therapeutics AS (NYKD.OL) compare to its historical average?